Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Q32 Bio Inc. (QTTB)
USD16.75
-1.71 (-9.26%)
US NASDAQ Healthcare Biotechnology
Address
830 Winter Street 2451
Waltham, MA, US
Waltham, MA, US
CEO
Jodie Pope Morrison
Website
q32bio.com
IPO
2018-03-28
CIK 1661998 ISIN US7469641051
Also trades on
London Stock Exchange · 0T6G.L (USD)
NASDAQ Global Market · QTTB (USD)
NASDAQ Global Select · FIXX (USD)
Description
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD16.75
-1.71 (-9.26%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
758.0K
Beta
-0.23
Float Shares
6.40M
Free Float %
50.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.47% | -5.39% | +112.79% | +85.34% | +327.03% | +280.72% | +656.89% | -32.48% | -90.50% | -96.24% | -96.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Hold
Price Targets & DCF
Current price
16.75
Low
13.00
-22.4%
Consensus
13.50
-19.4%
Median
13.50
-19.4%
High
14.00
-16.4%
DCF (Unlevered)
3.20
-80.9%
DCF (Levered)
2.25
-86.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
14.00
-16.4%
|
| Last Quarter | 1 |
14.00
-16.4%
|
| Last Year | 2 |
13.50
-19.4%
|
| All Time | 9 |
51.11
+205.1%
|
Quality scores
Altman Z-Score
3.86
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✓ MOAT relativo
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+136.8% ★ Q1'26: +40.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+22.6%
-
EBIT margin Biotechnology: +0.0%+31.5% ★
-
ROIC Biotechnology: -16.1%+186.5% ★ Q1'26: -471.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q1'26: +15.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.89× ★ Q1'26: -0.36× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.32M
est: 2.94M (+80.9%)
|
1.67M
est: 2.30M (-27.6%)
|
2.70M
est: 2.90M (-6.8%)
|
33.97M
est: 33.82M (+0.4%)
|
6.65M
est: 2.95M (+125.2%)
|
-6.65M
est: 1.16M (-675.3%)
|
—
est: 2.00M (-100.0%)
|
53.74M
est: 2.00M (+2,586.9%)
|
1.25M
1.25M – 1.25M
-37.5% YoY
|
1.25M
1.25M – 1.25M
+0.0% YoY
|
3.00M
3.00M – 3.00M
+140.0% YoY
|
45.71M
45.71M – 45.71M
+1,423.7% YoY
|
154.93M
154.93M – 154.93M
+238.9% YoY
|
| EBITDA |
-58.64M
est: -588.4K (-9,864.8%)
|
-97.60M
est: -460.1K (-21,113.0%)
|
-119.79M
est: -579.8K (-20,558.8%)
|
-86.22M
est: -6.76M (-1,174.6%)
|
-38.86M
est: -590.6K (-6,478.9%)
|
-47.76M
est: -231.2K (-20,555.8%)
|
-45.30M
est: 128.7K (-35,291.8%)
|
17.29M
est: 128.7K (+13,334.3%)
|
80.5K
80.5K – 80.5K
-37.5% YoY
|
80.5K
80.5K – 80.5K
+0.0% YoY
|
193.1K
193.1K – 193.1K
+140.0% YoY
|
2.94M
2.94M – 2.94M
+1,423.7% YoY
|
9.97M
9.97M – 9.97M
+238.9% YoY
|
| EBIT |
-55.58M
est: -588.4K (-9,344.8%)
|
-103.92M
est: -460.1K (-22,486.3%)
|
-128.69M
est: -579.8K (-22,094.4%)
|
-95.76M
est: -6.76M (-1,315.7%)
|
-39.23M
est: -590.6K (-6,541.6%)
|
-48.26M
est: -231.2K (-20,771.6%)
|
-45.79M
est: 125.8K (-36,493.2%)
|
16.90M
est: 125.8K (+13,334.3%)
|
78.6K
78.6K – 78.6K
-37.5% YoY
|
78.6K
78.6K – 78.6K
+0.0% YoY
|
188.7K
188.7K – 188.7K
+140.0% YoY
|
2.88M
2.88M – 2.88M
+1,423.7% YoY
|
9.75M
9.75M – 9.75M
+238.9% YoY
|
| Net Income |
-55.58M
est: -371.60M (+85.0%)
|
-103.92M
est: -568.97M (+81.7%)
|
-128.69M
est: -624.09M (+79.4%)
|
-95.76M
est: -366.66M (+73.9%)
|
-42.81M
est: -1.81M (-2,262.4%)
|
-53.74M
est: -434.72M (+87.6%)
|
-47.73M
est: -68.79M (+30.6%)
|
29.82M
est: -34.56M (+186.3%)
|
-22.65M
-25.10M – -20.20M
+34.5% YoY
|
-26.89M
-29.47M – -24.30M
-18.7% YoY
|
-27.64M
-36.53M – -18.74M
-2.8% YoY
|
-19.86M
-19.86M – -19.86M
+28.1% YoY
|
-9.98M
-9.98M – -9.98M
+49.8% YoY
|
| SGA |
16.01M
est: 6.23M (+156.9%)
|
15.89M
est: 4.87M (+226.2%)
|
23.67M
est: 6.14M (+285.4%)
|
27.29M
est: 71.65M (-61.9%)
|
10.06M
est: 6.26M (+60.9%)
|
9.88M
est: 2.45M (+303.3%)
|
17.47M
est: 864.2K (+1,921.8%)
|
17.68M
est: 864.2K (+1,945.7%)
|
540.1K
540.1K – 540.1K
-37.5% YoY
|
540.1K
540.1K – 540.1K
+0.0% YoY
|
1.30M
1.30M – 1.30M
+140.0% YoY
|
19.75M
19.75M – 19.75M
+1,423.7% YoY
|
66.95M
66.95M – 66.95M
+238.9% YoY
|
| EPS |
-35.04
est: -30.47 (-15.0%)
|
-44.41
est: -46.65 (+4.8%)
|
-50.46
est: -51.17 (+1.4%)
|
-31.18
est: -30.06 (-3.7%)
|
-13.42
est: -0.15 (-8,933.4%)
|
-16.70
est: -35.64 (+53.1%)
|
-5.12
est: -5.61 (+8.8%)
|
2.42
est: -2.81 (+186.2%)
|
-1.82
-2.04 – -1.64
+35.3% YoY
|
-2.23
-2.39 – -1.97
-22.8% YoY
|
-2.09
-2.97 – -1.52
+6.3% YoY
|
-1.61
-1.61 – -1.61
+22.8% YoY
|
-0.81
-0.81 – -0.81
+49.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-10 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-09 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-05 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-04 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-03 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-02 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-06-01 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-105.32M
OE per share TTM
-7.69
Owner's Yield
-59.12%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
145.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
53
Total invested
60.62M
Insider transactions (90d)
3
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 4.13M | 17.40% | — | 4.13M | — | 4.13M | IA | DE | 2026-06-01 | ↗ |
| 2 | ORBIMED CAPITAL GP VII LLC | 3.50M | 14.80% | — | 3.50M | — | 3.50M | OO | DE | 2026-06-01 | ↗ |
| 3 | RA Capital Management, L.P. | 2.33M | 9.80% | 2.33M | 2.33M | 2.33M | — | IA, PN | DELAWARE | 2026-06-04 | ↗ |
| 4 | Sirenia Capital Management LP | 2.06M | 9.90% | 2.06M | 2.06M | 2.06M | — | IA, PN | DELAWARE | 2026-05-15 | ↗ |
| 5 | Opaleye Management Inc. | 1.26M | 8.59% | 1.26M | 1.26M | 1.26M | — | IA, CO | MASSACHUSETTS | 2026-05-06 | ↗ |
| 6 | BIOTECHNOLOGY VALUE FUND L P | 1.25M | 5.30% | 1.25M | 1.25M | 1.25M | — | PN | DELAWARE | 2026-06-04 | ↗ |
| 7 | Abingworth Bioventures VII LP | 1.10M | 9.20% | — | 1.10M | — | 1.10M | PN | England and Wales | 2024-03-29 | ↗ |
| 8 | Abingworth LLP | 1.10M | 9.20% | — | 1.10M | — | 1.10M | PN | England and Wales | 2024-03-29 | ↗ |
| 9 | CG Subsidiary Holdings L.L.C. | 1.10M | 9.20% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-03-29 | ↗ |
| 10 | Carlyle Genesis UK LLC | 1.10M | 9.20% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-03-29 | ↗ |
| 11 | Carlyle Holdings I GP Inc. | 1.10M | 9.20% | — | 1.10M | — | 1.10M | CO | Delaware | 2024-03-29 | ↗ |
| 12 | Carlyle Holdings I GP Sub L.L.C. | 1.10M | 9.20% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-03-29 | ↗ |
| 13 | Carlyle Investment Management L.L.C. | 1.10M | 9.20% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-03-29 | ↗ |
| 14 | TC Group, L.L.C. | 1.10M | 9.20% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-03-29 | ↗ |
| 15 | Point72 Asset Management, L.P. | 958.8K | 5.70% | 958.8K | 958.8K | 958.8K | — | PN | DELAWARE | 2026-05-15 | ↗ |
| 16 | ATLAS VENTURE FUND X, L.P. | 864.3K | 7.20% | — | 864.3K | — | 10.00 | PN | Delaware | 2024-04-01 | ↗ |
| 17 | L.P. | 864.3K | 7.20% | — | 864.3K | — | 10.00 | PN | Delaware | 2024-04-01 | ↗ |
| 18 | LLC | 864.3K | 7.20% | — | 864.3K | — | 10.00 | OO | Delaware | 2024-04-01 | ↗ |
| 19 | ATLAS VENTURE ASSOCIATES X, L.P. | 864.3K | 3.60% | — | 864.3K | — | 864.3K | PN | DE | 2026-05-28 | ↗ |
| 20 | Acorn Bioventures, L.P. | 803.4K | 6.70% | — | 803.4K | — | 10.00 | PN | Delaware | 2024-04-04 | ↗ |
| 21 | Acorn Capital Advisors, GP, LLC | 803.4K | 6.70% | — | 803.4K | — | 10.00 | OO | Delaware | 2024-04-04 | ↗ |
| 22 | Anders Hove | 803.4K | 6.70% | — | 803.4K | — | 10.00 | IN | United States | 2024-04-04 | ↗ |
| 23 | Bristol-Myers Squibb Company | 759.1K | 6.23% | 759.1K | — | 759.1K | — | CO | Delaware | 2024-11-13 | ↗ |
| 24 | FUND II, L.P. | 724.5K | 6.10% | — | 724.5K | — | 10.00 | PN | Delaware | 2024-04-01 | ↗ |
| 25 | II, L.P. | 724.5K | 6.10% | — | 724.5K | — | 10.00 | PN | Delaware | 2024-04-01 | ↗ |
| 26 | Atlas Venture Associates Opportunity II, L.P. | 724.5K | 3.10% | — | 724.5K | — | 724.5K | PN | DE | 2026-05-28 | ↗ |
| 27 | Atlas Venture Opportunity Fund II, L.P. | 724.5K | 3.10% | — | 724.5K | — | 724.5K | PN | DE | 2026-05-28 | ↗ |
| 28 | Atlas Venture Associates Opportunity III, L.P. | 625.0K | 2.60% | — | 625.0K | — | 625.0K | PN | DE | 2026-05-28 | ↗ |
| 29 | Atlas Venture Opportunity Fund Ill, L.P. | 625.0K | 2.60% | — | 625.0K | — | 625.0K | PN | DE | 2026-05-28 | ↗ |
| 30 | OrbiMed Genesis GP LLC | 625.0K | 2.60% | — | 625.0K | — | 625.0K | OO | DE | 2026-06-01 | ↗ |
| 31 | FUND I, L.P. | 503.3K | 4.20% | — | 503.3K | — | 10.00 | PN | Delaware | 2024-04-01 | ↗ |
| 32 | I, L.P. | 503.3K | 4.20% | — | 503.3K | — | 10.00 | PN | Delaware | 2024-04-01 | ↗ |
| 33 | Atlas Venture Associates Opportunity I, L.P. | 503.3K | 2.10% | — | 503.3K | — | 503.3K | PN | DE | 2026-05-28 | ↗ |
| 34 | Atlas Venture Opportunity Fund I, L.P. | 503.3K | 2.10% | — | 503.3K | — | 503.3K | PN | DE | 2026-05-28 | ↗ |
| 35 | BRISTOL MYERS SQUIBB CO | 200.2K | 1.64% | — | — | — | — | CO | DELAWARE | 2025-02-14 | ↗ |
| 36 | Sio Capital Management, LLC | — | 0.00% | — | — | — | — | IA | DELAWARE | 2025-04-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
53
+2 vs prev Q
New positions
12
Closed positions
10
Increased
26
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 2.25M +— (+0.0%) | 7.48M +3.0M (+67.7%) | 18.41% -0.065 pp | 0.15% +0.048 pp | USD18.00 -81.6% | 8 qtrs — |
| 2 | ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 2.09M +— (+0.0%) | 6.95M +2.8M (+67.7%) | 17.09% -0.060 pp | 0.80% +0.253 pp | USD18.00 -81.6% | 8 qtrs — |
| 3 | CARLYLE GROUP INC. | 1.10M +— (+0.0%) | 3.62M +1.5M (+69.9%) | 9.01% -0.032 pp | 0.03% -0.022 pp | USD18.00 -81.6% | 8 qtrs — |
| 4 | ACORN CAPITAL ADVISORS, LLC | 493.4K -310.0K (-38.6%) | 1.64M +47.4K (+3.0%) | 4.03% -2.556 pp | 0.56% -0.253 pp | USD3.44 -3.5% | 5 qtrs — |
| 5 | VANGUARD GROUP INC | 321.1K +25.6K (+8.7%) | 1.07M +481.0K (+82.2%) | 2.62% +0.201 pp | 0.00% +0.000 pp | USD24.79 -86.6% | 8 qtrs — |
| 6 | ARCH VENTURE MANAGEMENT, LLC | 320.5K +— (+0.0%) | 1.06M +429.4K (+67.7%) | 2.62% -0.009 pp | 0.16% +0.034 pp | USD18.00 -81.6% | 8 qtrs — |
| 7 | PFIZER INC | 277.8K +— (+0.0%) | 922.2K +372.2K (+67.7%) | 2.27% -0.008 pp | 0.39% +0.264 pp | USD3.44 -3.5% | 5 qtrs — |
| 8 | SANOFI | 244.1K +— (+0.0%) | 810.4K +327.1K (+67.7%) | 1.99% -0.007 pp | 0.26% +0.075 pp | USD3.44 -3.5% | 5 qtrs — |
| 9 | OPALEYE MANAGEMENT INC. | 213.4K +213.4K (+100.0%) | 708.4K +708.4K (+100.0%) | 1.74% +1.743 pp | 0.09% +0.094 pp | USD3.32 +0.0% | 1 qtrs NEW |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 106.1K +17.6K (+19.9%) | 352.4K +177.1K (+101.0%) | 0.87% +0.141 pp | 0.00% +0.000 pp | USD14.20 -76.6% | 8 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 99.6K +52.3K (+110.6%) | 330.7K +237.0K (+253.1%) | 0.81% +0.426 pp | 0.00% +0.000 pp | USD2.45 +35.5% | 3 qtrs — |
| 12 | BLACKROCK, INC. | 59.9K -33.1K (-35.6%) | 199.0K +14.8K (+8.0%) | 0.49% -0.273 pp | 0.00% +0.000 pp | USD39.44 -91.6% | 6 qtrs — |
| 13 | MILLENNIUM MANAGEMENT LLC | 51.3K -53.5K (-51.1%) | 170.2K -37.2K (-18.0%) | 0.42% -0.440 pp | 0.00% +0.000 pp | USD1.49 +122.8% | 6 qtrs — |
| 14 | MONACO ASSET MANAGEMENT SAM | 50.9K -260.2K (-83.6%) | 169.1K -447.0K (-72.6%) | 0.42% -2.135 pp | 0.03% -0.008 pp | USD3.16 +5.1% | 5 qtrs — |
| 15 | ACADIAN ASSET MANAGEMENT LLC | 48.4K +18.6K (+62.7%) | 159.0K +101.0K (+174.1%) | 0.40% +0.151 pp | 0.00% +0.000 pp | USD2.29 +45.0% | 4 qtrs — |
| 16 | TWO SIGMA INVESTMENTS, LP | 46.8K +15.3K (+48.6%) | 155.5K +93.1K (+149.2%) | 0.38% +0.124 pp | 0.00% +0.000 pp | USD2.42 +37.2% | 2 qtrs — |
| 17 | CITADEL ADVISORS LLC | 45.7K +35.6K (+352.0%) | 151.8K +131.8K (+657.9%) | 0.37% +0.291 pp | 0.00% +0.000 pp | USD3.02 +9.9% | 2 qtrs — |
| 18 | AFFINITY ASSET ADVISORS, LLC | 27.8K +— (+0.0%) | 92.2K +37.2K (+67.7%) | 0.23% -0.001 pp | 0.01% +0.001 pp | USD18.00 -81.6% | 8 qtrs — |
| 19 | JANE STREET GROUP, LLC | 25.4K +25.4K (+100.0%) | 84.2K +84.2K (+100.0%) | 0.21% +0.207 pp | 0.00% +0.000 pp | USD3.32 +0.0% | 3 qtrs — |
| 20 | NORTHERN TRUST CORP | 25.0K -6.9K (-21.7%) | 83.1K +19.8K (+31.4%) | 0.20% -0.058 pp | 0.00% +0.000 pp | USD36.75 -91.0% | 6 qtrs — |
| 21 | HRT FINANCIAL LP | 24.7K +9.9K (+66.5%) | 81.0K +52.0K (+179.3%) | 0.20% +0.080 pp | 0.00% +0.000 pp | USD2.52 +31.7% | 2 qtrs — |
| 22 | STATE STREET CORP | 21.2K +— (+0.0%) | 70.5K +28.5K (+67.7%) | 0.17% -0.001 pp | 0.00% +0.000 pp | USD20.99 -84.2% | 7 qtrs — |
| 23 | XTX TOPCO LTD | 20.4K +20.4K (+100.0%) | 67.6K +67.6K (+100.0%) | 0.17% +0.166 pp | 0.00% +0.002 pp | USD3.32 +0.0% | 1 qtrs NEW |
| 24 | ADAR1 CAPITAL MANAGEMENT, LLC | 20.0K +20.0K (+100.0%) | 66.4K +66.4K (+100.0%) | 0.16% +0.163 pp | 0.00% +0.005 pp | USD3.32 +0.0% | 1 qtrs NEW |
| 25 | SCIENTECH RESEARCH LLC | 15.5K +15.5K (+100.0%) | 51.5K +51.5K (+100.0%) | 0.13% +0.127 pp | 0.03% +0.032 pp | USD3.32 +0.0% | 1 qtrs NEW |
| 26 | UBS GROUP AG | 13.6K +8.4K (+159.4%) | 45.2K +34.8K (+334.9%) | 0.11% +0.068 pp | 0.00% +0.000 pp | USD4.02 -17.4% | 8 qtrs — |
| 27 | MORGAN STANLEY | 5.5K -5.9K (-51.7%) | 18.2K -4.3K (-19.0%) | 0.04% -0.048 pp | 0.00% +0.000 pp | USD8.48 -60.8% | 8 qtrs — |
| 28 | EVERSOURCE WEALTH ADVISORS, LLC | 4.6K -385.0 (-7.7%) | 15.4K +5.5K (+54.8%) | 0.04% -0.003 pp | 0.00% +0.000 pp | USD1.49 +122.8% | 5 qtrs — |
| 29 | FMR LLC | 3.4K -12.5K (-78.8%) | 11.2K -20.2K (-64.5%) | 0.03% -0.103 pp | 0.00% +0.000 pp | USD27.00 -87.7% | 8 qtrs — |
| 30 | FEDERATED HERMES, INC. | 2.3K -101.0 (-4.3%) | 7.5K +2.8K (+60.5%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.77 -11.9% | 6 qtrs — |
| 31 | GLOBAL RETIREMENT PARTNERS, LLC | 1.5K -3.5K (-70.0%) | 5.0K -4.9K (-49.7%) | 0.01% -0.029 pp | 0.00% 0.000 pp | USD1.98 +67.7% | 2 qtrs — |
| 32 | SRS CAPITAL ADVISORS, INC. | 1.1K -104.0 (-8.6%) | 3.7K +1.3K (+53.4%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.53 +117.0% | 3 qtrs — |
| 33 | BANK OF AMERICA CORP /DE/ | 1.0K -490.0 (-32.1%) | 3.4K +416.0 (+13.8%) | 0.01% -0.004 pp | 0.00% +0.000 pp | USD17.69 -81.2% | 8 qtrs — |
| 34 | TOWER RESEARCH CAPITAL LLC (TRC) | 976.00 -5.5K (-84.9%) | 3.2K -9.6K (-74.8%) | 0.01% -0.045 pp | 0.00% 0.000 pp | USD2.45 +35.5% | 7 qtrs — |
| 35 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 577.00 +— (+0.0%) | 1.9K +774.0 (+67.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.98 +67.7% | 2 qtrs — |
| 36 | JONES FINANCIAL COMPANIES LLLP | 500.00 +500.0 (+100.0%) | 1.7K +1.7K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD3.32 +0.0% | 1 qtrs NEW |
| 37 | RUSSELL INVESTMENTS GROUP, LTD. | 454.00 +— (+0.0%) | 1.5K +608.0 (+67.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.08 -34.6% | 6 qtrs — |
| 38 | JPMORGAN CHASE & CO | 324.00 +320.0 (+8,000.0%) | 1.1K +1.1K (+13,350.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD3.30 +0.6% | 8 qtrs — |
| 39 | BNP PARIBAS ARBITRAGE, SNC | 308.00 -124.0 (-28.7%) | 1.0K +168.0 (+19.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD33.75 -90.2% | 7 qtrs — |
| 40 | ROYAL BANK OF CANADA | 235.00 -818.0 (-77.7%) | 1.0K -1.0K (-50.0%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD4.02 -17.4% | 8 qtrs — |
| 41 | NISA INVESTMENT ADVISORS, LLC | 166.00 +— (+0.0%) | 551.00 +222.0 (+67.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.49 +122.8% | 6 qtrs — |
| 42 | SBI SECURITIES CO., LTD. | 157.00 -8.0K (-98.1%) | 521.00 -15.6K (-96.8%) | 0.00% -0.066 pp | 0.00% 0.000 pp | USD1.52 +118.4% | 5 qtrs — |
| 43 | ADVISOR GROUP HOLDINGS, INC. | 132.00 -55.0 (-29.4%) | 437.00 +70.0 (+19.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD25.70 -87.1% | 8 qtrs — |
| 44 | ALLWORTH FINANCIAL LP | 98.00 -512.0 (-83.9%) | 326.00 -882.0 (-73.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD2.01 +65.2% | 5 qtrs — |
| 45 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 70.00 +— (+0.0%) | 231.00 +94.0 (+68.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.51 -68.4% | 8 qtrs — |
| 46 | GROUP ONE TRADING, L.P. | 34.00 +— (+0.0%) | 113.00 +46.0 (+68.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.97 +68.5% | 2 qtrs — |
| 47 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 30.00 +30.0 (+100.0%) | 100.00 +100.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.30 +0.6% | 1 qtrs NEW |
| 48 | BARCLAYS PLC | 19.00 -10.4K (-99.8%) | 63.00 -465.9K (-100.0%) | 0.00% -0.086 pp | 0.00% 0.000 pp | USD4.53 -26.7% | 8 qtrs — |
| 49 | HARBOUR INVESTMENTS, INC. | 11.00 +— (+0.0%) | 37.00 +15.0 (+68.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.91 -82.4% | 7 qtrs — |
| 50 | ADVISORNET FINANCIAL, INC | 2.00 +— (+0.0%) | 7.00 +3.0 (+75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.50 -81.0% | 8 qtrs — |
| 51 | DANSKE BANK A/S | 1.00 +— (+0.0%) | 3.00 +1.0 (+50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD44.00 -92.5% | 6 qtrs — |
| 52 | GF FUND MANAGEMENT CO. LTD. | — -227.0 (-100.0%) | — -449.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 53 | CITIGROUP INC | — -236.0 (-100.0%) | — -467.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 54 | DLK INVESTMENT MANAGEMENT, LLC | — -10.3K (-100.0%) | — -20.5K (-100.0%) | 0.00% -0.085 pp | 0.00% -0.008 pp | USD— | 3 qtrs SOLD |
| 55 | ST GERMAIN D J CO INC | — -11.0 (-100.0%) | — -22.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 56 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | — -472.0 (-100.0%) | — -935.0 (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 57 | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | — -133.9K (-100.0%) | — -265.1K (-100.0%) | 0.00% -1.098 pp | 0.00% -0.041 pp | USD— | 5 qtrs SOLD |
| 58 | TWO SIGMA SECURITIES, LLC | — -13.7K (-100.0%) | — -27.2K (-100.0%) | 0.00% -0.113 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 59 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -2.1K (-100.0%) | — -4.2K (-100.0%) | 0.00% -0.018 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 21 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 111.3K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.02% | 330.3K | 0.60% |
| 3 | Avantis U.S. Small Cap Value ETF AVUV | 0.01% | 2.83M | 0.25% |
| 4 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.00% | 53.4K | 0.39% |
| 5 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 107.1K | 0.25% |
| 6 | Avantis U.S. Equity ETF AVUS | 0.00% | 200.1K | 0.15% |
| 7 | Vanguard Extended Market ETF VXF | 0.00% | 1.29M | 0.05% |
| 8 | Dimensional - US Small Cap ETF DFAS | 0.00% | 184.6K | 0.26% |
| 9 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 62.9K | 0.43% |
| 10 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 891.89 | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
3
Sells
3
Shares acquired
60.0K
Shares disposed
16.7K
Cash buys
—
Cash sales
3.00
Net activity
+43,292
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | Xu Diyong | Director / 10% Owner | P-Purchase | A | Common Stock | 1,250,000 | 8.00 | 10.00M | 3,502,987 | I | ↗ |
| 2026-05-28 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 1,250,000 | 8.00 | 10.00M | 3,502,987 | I | ↗ |
| 2026-05-26 | Atlas Venture Opportunity Fund Ill, L.P. | Other | — | — | Common Stock | 0 | 0.00 | — | 625,000 | D | ↗ |
| 2026-02-25 | Violette Shelia M. | Officer | S-Sale | D | Common Stock | 2,815 | 4.51 | 12.7K | 55,569 | D | ↗ |
| 2026-02-25 | Morrison Jodie Pope | Director / Officer | S-Sale | D | Common Stock | 9,896 | 4.51 | 44.7K | 89,104 | D | ↗ |
| 2026-02-25 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 3,995 | 4.51 | 18.0K | 35,943 | D | ↗ |
| 2026-02-24 | Violette Shelia M. | Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 93,069 | D | ↗ |
| 2026-02-24 | Morrison Jodie Pope | Director / Officer | A-Award | A | Common Stock | 132,000 | 0.00 | — | 221,104 | D | ↗ |
| 2026-02-24 | Kalowski Lee | Officer | A-Award | A | Common Stock | 53,250 | 0.00 | — | 89,193 | D | ↗ |
| 2026-01-15 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (Right to Buy) | 20,363 | 3.60 | 73.3K | 20,363 | D | ↗ |
| 2026-01-15 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 23,272 | 3.60 | 83.8K | 23,272 | D | ↗ |
| 2026-01-15 | GRAYZEL DAVID S. | Director | A-Award | A | Stock Option (Right to Buy) | 16,363 | 3.60 | 58.9K | 16,363 | D | ↗ |
| 2025-12-02 | Morrison Jodie Pope | Director / Officer | S-Sale | D | Common Stock | 22,506 | 3.46 | 77.9K | 99,000 | D | ↗ |
| 2025-12-02 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 9,072 | 3.46 | 31.4K | 39,938 | D | ↗ |
| 2025-10-23 | Xu Diyong | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | Thistle Mary | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | TZIANABOS ARTHUR | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | Manke Isaac | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-10-23 | GRAYZEL DAVID S. | Director | A-Award | A | Stock Option (Right to Buy) | 53,521 | 2.80 | 149.9K | 53,521 | D | ↗ |
| 2025-08-26 | Violette Shelia M. | Officer | S-Sale | D | Common Stock | 2,990 | 1.80 | 5.4K | 58,384 | D | ↗ |
| 2025-08-26 | Morrison Jodie Pope | Director / Officer | S-Sale | D | Common Stock | 10,494 | 1.80 | 18.9K | 121,506 | D | ↗ |
| 2025-08-26 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 4,240 | 1.80 | 7.6K | 49,010 | D | ↗ |
| 2025-02-24 | Xu Diyong | Director | A-Award | A | Stock Option (Right to Buy) | 12,767 | 2.54 | 32.4K | 12,767 | D | ↗ |
| 2025-02-24 | Violette Shelia M. | Officer | D-Return | D | Stock Option (Right to Buy) | 17,506 | 7.50 | 131.3K | 0 | D | ↗ |
| 2025-02-24 | Thistle Mary | Director | D-Return | D | Stock Option (Right to Buy) | 12,767 | 16.82 | 214.7K | 0 | D | ↗ |
| 2025-02-24 | TZIANABOS ARTHUR | Director | D-Return | D | Stock Option (Right to Buy) | 25,674 | 7.09 | 182.0K | 0 | D | ↗ |
| 2025-02-24 | Morrison Jodie Pope | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 16,901 | 2.54 | 42.9K | 16,901 | D | ↗ |
| 2025-02-24 | Manke Isaac | Director | A-Award | A | Stock Option (Right to Buy) | 19,008 | 2.53 | 48.1K | 19,008 | D | ↗ |
| 2025-02-24 | Lundberg Sven Ante | Director | D-Return | D | Stock Option (Right to Buy) | 23,140 | 3.20 | 74.0K | 0 | D | ↗ |
| 2025-02-24 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 12,767 | 2.54 | 32.4K | 12,767 | D | ↗ |
| 2025-02-24 | Kalowski Lee | Officer | A-Award | A | Common Stock | 53,250 | 0.00 | — | 53,250 | D | ↗ |
| 2025-02-24 | Iwicki Mark T | Director | D-Return | D | Stock Option (Right to Buy) | 25,534 | 16.82 | 429.5K | 0 | D | ↗ |
| 2025-02-24 | GRAYZEL DAVID S. | Director | A-Award | A | Stock Option (Right to Buy) | 18,595 | 2.54 | 47.2K | 18,595 | D | ↗ |
| 2025-02-24 | Campagna Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 70,687 | 2.54 | 179.5K | 70,687 | D | ↗ |
| 2025-01-15 | Manke Isaac | Director | A-Award | A | Stock Option (Right to Buy) | 19,008 | 3.20 | 60.8K | 19,008 | D | ↗ |
| 2025-01-15 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (Right to Buy) | 23,140 | 3.20 | 74.0K | 23,140 | D | ↗ |
| 2025-01-15 | GRAYZEL DAVID S. | Director | A-Award | A | Stock Option (Right to Buy) | 18,595 | 3.20 | 59.5K | 18,595 | D | ↗ |
| 2024-10-15 | Violette Shelia M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,000 | 7.29 | 43.7K | 32,891 | D | ↗ |
| 2024-10-11 | Violette Shelia M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,361 | 3.12 | 13.6K | 0 | D | ↗ |
| 2024-10-08 | Violette Shelia M. | Officer | M-Exempt | A | Common Stock | 13,300 | 3.12 | 41.5K | 13,300 | D | ↗ |
| 2024-09-25 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (Right to Buy) | 1,316 | 44.40 | 58.4K | 1,316 | D | ↗ |
| 2024-04-01 | Manke Isaac | Director | A-Award | A | Stock Option (Right to Buy) | 2,627 | 18.00 | 47.3K | 2,627 | D | ↗ |
| 2024-04-01 | GRAYZEL DAVID S. | Director | A-Award | A | Stock Option (Right to Buy) | 2,569 | 18.00 | 46.2K | 2,569 | — | ↗ |
| 2024-03-25 | Xu Diyong | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,252,987 | — | ↗ |
| 2024-03-25 | Violette Shelia M. | Officer | — | D | Stock Option (Right to Buy) | 13,513 | 3.13 | 42.3K | 0 | — | ↗ |
| 2024-03-25 | Thistle Mary | Director | A-Award | A | Stock Option (Right to Buy) | 12,767 | 16.82 | 214.7K | 12,767 | — | ↗ |
| 2024-03-25 | TZIANABOS ARTHUR | Director | M-Exempt | A | Common Stock | 1,095 | 0.00 | — | 8,248 | — | ↗ |
| 2024-03-25 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,252,987 | — | ↗ |
| 2024-03-25 | Morrison Jodie Pope | Director / Officer | — | D | Stock Option (Right to Buy) | 16,901 | 17.08 | 288.7K | 0 | — | ↗ |
| 2024-03-25 | Michaud Charles Jr | Officer | S-Sale | D | Common Stock | 75 | 24.20 | 1.8K | 927 | — | ↗ |
| 2024-03-25 | Manke Isaac | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-25 | Lundberg Sven Ante | Director | — | D | Stock Option (Right to Buy) | 6,238 | 3.13 | 19.5K | 0 | — | ↗ |
| 2024-03-25 | LAPORTE KATHLEEN | Director | — | D | Stock Option (Right to Buy) | 1,947 | 7.29 | 14.2K | 0 | — | ↗ |
| 2024-03-25 | Kalowski Lee | Officer | — | D | Stock Option (Right to Buy) | 16,901 | 17.08 | 288.7K | 0 | — | ↗ |
| 2024-03-25 | Iwicki Mark T | Director | — | D | Stock Option (Right to Buy) | 7,615 | 7.29 | 55.5K | 0 | — | ↗ |
| 2024-03-25 | GRAYZEL DAVID S. | Director | — | I | Common Stock | 0 | 0.00 | — | 724,549 | — | ↗ |
| 2024-03-25 | Campagna Jason | Officer | — | D | Stock Option (Right to Buy) | 17,951 | 7.29 | 130.9K | 0 | — | ↗ |
| 2024-03-25 | Atlas Venture Fund X, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 864,261 | — | ↗ |
| 2024-03-25 | Alloway Paul | Officer | S-Sale | D | Common Stock | 268 | 24.21 | 6.5K | 2,596 | — | ↗ |
Executive team
Top executives
EBIT / Employee
603.6K
Shares Outstanding
12.78M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jodie Pope Morrison | Chief Executive Officer & Director | 1M | female |
| Lee H. Kalowski | Chief Financial Officer & President | 792.8K | male |
| Shelia Violette | Co-founder, Chief Scientific Officer & President of Research | 641.9K | — |
| David Appugliese | Senior Vice President & Head of People | — | male |
| Maria Marzilli | Chief Business Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for QTTB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
